Astria Therapeutics, Inc. (NASDAQ:ATXS) Receives Average Rating of “Hold” from Analysts

Astria Therapeutics, Inc. (NASDAQ:ATXS) has been assigned a consensus rating of “Hold” from the eleven ratings firms that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and two have assigned a buy rating to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $24.50.

Several equities analysts have recently weighed in on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Astria Therapeutics in a research note on Wednesday, January 21st. Cantor Fitzgerald cut Astria Therapeutics from an “overweight” rating to a “neutral” rating in a report on Wednesday, November 12th. Finally, Lifesci Capital cut shares of Astria Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, November 12th.

Astria Therapeutics Stock Performance

ATXS opened at $12.58 on Tuesday. Astria Therapeutics has a fifty-two week low of $3.56 and a fifty-two week high of $13.29. The company has a fifty day moving average of $12.74 and a two-hundred day moving average of $10.61. The stock has a market capitalization of $718.13 million, a price-to-earnings ratio of -5.88 and a beta of 0.01.

Hedge Funds Weigh In On Astria Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Glazer Capital LLC acquired a new stake in shares of Astria Therapeutics during the fourth quarter worth about $49,430,000. UBS Group AG lifted its holdings in Astria Therapeutics by 313.5% during the 4th quarter. UBS Group AG now owns 2,399,171 shares of the biotechnology company’s stock worth $31,405,000 after buying an additional 1,819,020 shares in the last quarter. Deutsche Bank AG lifted its holdings in Astria Therapeutics by 5,187.5% during the 4th quarter. Deutsche Bank AG now owns 1,762,802 shares of the biotechnology company’s stock worth $23,075,000 after buying an additional 1,729,463 shares in the last quarter. JPMorgan Chase & Co. boosted its position in Astria Therapeutics by 4,607.1% in the 2nd quarter. JPMorgan Chase & Co. now owns 1,696,071 shares of the biotechnology company’s stock valued at $9,091,000 after buying an additional 1,660,039 shares during the period. Finally, Soros Fund Management LLC acquired a new position in shares of Astria Therapeutics in the fourth quarter worth $11,433,000. 98.98% of the stock is currently owned by hedge funds and other institutional investors.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the development of innovative immunotherapies for oncology and autoimmune diseases. The company leverages proprietary cell engineering platforms to create next‐generation agents that engage T cells and natural killer (NK) cells, with the goal of directing potent and specific immune responses against tumor‐associated antigens or diseased tissues.

Astria’s pipeline encompasses multiple therapeutic candidates across both hematologic and solid tumor indications, as well as autoimmune disorders.